AdjuTec Pharma – Phase I Clinical Study Results for APC148 Published

Oslo, Norway, 23 June 2026 – AdjuTec Pharma AS, a privately held company developing antibiotic resistance breakers, is pleased to announce the publication of the Phase I clinical study evaluating APC148, AdjuTec Pharma’s novel metallo-β-lactamase (MBL) inhibitor, in healthy volunteers.

The study, titled “Phase I dose-ascending, safety, and pharmacokinetics study of APC148, a novel metallo-β-lactamase inhibitor, in healthy volunteers”, has been published in Antimicrobial Agents and Chemotherapy.

The Phase I trial assessed the safety, tolerability, and pharmacokinetic profile of APC148 in healthy participants through a dose-escalation design. The results demonstrated that APC148 was well tolerated and supported its continued clinical development as a potential solution to combat antibiotic-resistant bacterial infections caused by MBL-producing pathogens.

The publication represents an important milestone in the development of APC148 and further strengthens the scientific foundation of AdjuTec Pharma’s mission to address the growing global threat of antimicrobial resistance.

The full publication is available here

Full PR available here